| Price | 13,284.00p on 17-06-2026 at 05:18:25 |
|---|---|
| Change | 0.00p 0% |
| Buy | 13,500.00p |
| Sell | 13,000.00p |
| Last Trade: | Unknown 0.00 at 13,306.27521p |
| Day's Volume: | 0 |
| Last Close: | 13,284.00p |
| Open: | 0.00p |
| ISIN: | GB0009895292 |
| Day's Range | 0.00p - 0.00p |
| 52wk Range: | 10,104.00p - 15,730.00p |
| Market Capitalisation: | £206.02b |
| VWAP: | 0.00p |
| Shares in Issue: | 1.55b |
Astrazeneca (AZN) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 0 | 13,306.27521p | Currency Conversion OTC Trade |
20:21:46 - 16-Jun-26 |
| Unknown* | 0 | 13,288.40044p | SI Trade Currency Conversion |
20:10:21 - 16-Jun-26 |
| Unknown* | 0 | 13,292.86914p | SI Trade Currency Conversion |
20:01:15 - 16-Jun-26 |
| Unknown* | 0 | 13,309.99912p | SI Trade Currency Conversion |
19:48:32 - 16-Jun-26 |
| Unknown* | 0 | 13,321.17085p | SI Trade Currency Conversion |
19:33:51 - 16-Jun-26 |
| Unknown* | 0 | 13,333.24025p | SI Trade Currency Conversion |
19:11:11 - 16-Jun-26 |
| Unknown* | 4 | 13,352.64057p | Currency Conversion Negotiated Trade OTC Trade |
18:59:27 - 16-Jun-26 |
| Unknown* | 3 | 13,348.90974p | SI Trade Currency Conversion |
18:46:52 - 16-Jun-26 |
| Unknown* | 0 | 13,345.92508p | SI Trade Currency Conversion |
18:42:44 - 16-Jun-26 |
| Unknown* | 0 | 13,336.22492p | SI Trade Currency Conversion |
18:37:24 - 16-Jun-26 |
Astrazeneca (AZN) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 15th Jun 2026 7:00 am | RNS | Truqap approved in US for prostate cancer |
| 1st Jun 2026 3:05 pm | RNS | Admission of Further Securities to Trading |
| 1st Jun 2026 3:00 pm | RNS | Total Voting Rights |
| 29th May 2026 7:00 am | RNS | Imfinzi approved in US for early bladder cancer |
| 27th May 2026 7:00 am | RNS | US FDA decision date on camizestrant extended |
| 26th May 2026 7:00 am | RNS | Enhertu recommended in EU for HER2+ solid tumours |
| 26th May 2026 7:00 am | RNS | Camizestrant recommended for breast cancer in EU |
| 26th May 2026 7:00 am | RNS | Datroway approved in US for 1L triple-negative BC |
| 18th May 2026 3:00 pm | RNS | Director/PDMR Shareholding |
| 18th May 2026 7:05 am | RNS | Enhertu approved in two HER2+ early BC settings |
